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Abstract
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disorder of the
central nervous system. Although there are no pathognomonic features to confirm
the diagnosis of this immune-mediated disease, a constellation of clinical, radiolog-
ical, and immune studies can ensure the clinician gets a more definitive diagnosis.
Criteria have been made every few years based on research to clinch the diagnosis.
The most recent criteria which are the McDonald criteria have been formed in 2001
and revised in 2005, 2010, and 2017. Most criteria are to be used only as a guide to
facilitate the diagnosis of multiple sclerosis. Advances in demyelinating disorders
will require diagnostic criteria to be revised every few years with scientists hoping
for a more definitive and confirmative diagnosis. The cardinal features for diagnosis
are dissemination in time and space. There should be no other possible explanation
to the clinical features.
Keywords: multiple sclerosis, diagnosis, criteria, dissemination in time,
dissemination in space
1. Introduction
Multiple sclerosis is an immune-mediated disease involving the central nervous
system predominantly affecting the brain, spinal cord, and optic nerves. There is
no gold standard or pathognomonic features that can distinguish MS from other
neurological conditions with multiple anatomical site involvement. A comprehen-
sive history obtained from the patient, clinical examination with the support of
laboratory investigations with is required to assist in the diagnosis of MS. The key to
diagnosis has always been dissemination in time, which translates into different
time interval of clinical relapse, and dissemination of space, which is a variable
anatomical site in the central nervous system. Hence difference in time and neuro-
anatomical site is essential. Several criteria have been created over the last several
decades such as Schumacher criteria, [1], Poser criteria [2], and McDonald criteria
[3–5]. McDonald criteria has been first established in 2001 and revised in 2005,
2010, and 2017. Revisions are necessary due to evolving research and advances in
the field of demyelinating diseases. Researchers in neuroimmunology diseases
concurred the diagnosis of MS could be made earlier and can be used for paediatric
population and Asian patients [5]. Investigations are done for diagnosis of MS to
ensure there are no other possible explanations for the clinical and radiological
presentation. As the patient can be subjected to lifelong immune modulators and
immunosuppressant, it is highly essential to ensure diagnosis is made accurately and
possible differentials are monitored during follow-up. A clinician’s job does not end
with establishing diagnosis and instituting treatment. Careful surveillance is neces-
sary to ensure we are in the right track as regards to the diagnosis. Misdiagnosis
1
could still occur, and therefore it must be addressed, and measures should be
undertaken to minimise them.
2. Making the diagnosis: symptoms and signs
Awareness about MS is crucial for the patient to seek attention, and to ask for a
second opinion when necessary is important both for patients and healthcare pro-
viders. A good history with a knowledge of common presentations and bearing in
mind neuroanatomical sites involved will be valuable in coming to a conclusion, and
focused investigations will be needed. Knowledge of subtypes and classification will
be helpful to the clinician.
Four subtypes of multiple sclerosis are used [6].
Active or disease activity is measured by clinical relapses and MRI evidence of
contrast-enhanced lesion or new or enlarging lesion on T2-weighted images by
annual clinical assessment.
Progression-progressive disability by annual clinical assessment
If no annual assessment is done, it is called indeterminate.
• Clinically isolated syndrome
◦ Active
◦ Not active
• Relapsing-remitting multiple sclerosis
◦ Active
◦ Not active
• Primary progressive disease
◦ Active with progression
◦ Active but without progression
◦ Not active but with progression
◦ Not active and without progression
• Secondary progressive disease
◦ Active with progression
◦ Active but without progression
2.1 Optic nerve
Optic nerve involvements are common and often the first presentation in mul-
tiple sclerosis [7]. The severity can vary from being asymptomatic to severe visual
loss, and recovery could be complete, partial, or no resolution. The symptoms could
begin as pain behind the eye and evolve into visual impairment in the centre of the
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eye and may worsen till visual acuity is lost. Diminished colour appreciation or
dyschromatopsia may be seen. The pain associated with ON tends to progress over
days. Visual improvement may occur in 3–8 weeks, and most visual recovery occurs
within the first 6 months but can continue for up to 1 year after the acute event
[8–12]. However, many patients may experience residual and variable visual com-
plaints and dysfunction after recovery. Examination on optic neuritis could reveal
no abnormalities, and deficits are present; there may be disc selling, fine
haemorrhages, impaired visual acuity, central or centrocecal oedema, relative
afferent pupillary defect or Marcus Gunn pupil, impaired colour vision, and pale
optic discs [11]. Phosphenes, which are an experience of bright flashes of light
without light entering the eye, Uhthoff’s phenomenon where there is brief blurring
of vision during physical exercise [13].
2.2 Spinal cord
Numbness and weakness of upper and or lower limbs are presentations seen in
spinal cord lesions in MS [14]. Cord lesions also come with urinary incontinence,
frequency, and urinary retention depending on the level and severity involved.
Constipation and diarrhoea could relate to bowel dysfunction. The symptoms are of
corticospinal tract lesion; a clear sensory level might guide the clinician to focus on a
cord lesion rather than a peripheral lesion due to a lower motor neuron lesion.
Clinical assessment may reveal increased tone, monoparesis, hemiparesis and
quadriparesis, abnormal cutaneous and sensory deficit, and sphincter disturbance
[14]. The clinical diagnosis involving the cord is called myelitis.
2.3 Brainstem
Double vision, speech difficulty, swallowing difficulty, nausea, vomiting, hic-
cups, vertigo, unsteadiness, and weakness of limbs are symptoms seen in brainstem
lesions. Examination would reveal nystagmus, ophthalmoplegia, dysarthria, and
facial weakness [14]. Cranial nerve deficits involving III–XII may be seen. Cerebel-
lar connection with the brainstem can cause dysdiadochokinesia, dysmetria, and
ataxia [15]. Brainstem lesions could also cause respiratory failure and locked-in
syndrome. Localization of the neuroanatomical site can be judged based on the
symptoms prior to neuroimaging.
2.4 Cerebellum
Unsteadiness involving upper and lower limbs, gait instability, and dysarthria
are common symptoms seen in structures involving the cerebellum. Tremors,
which are either due to cerebellar or thalamic involvement, could occur, and they
result in tremor affecting limbs, trunk, and vocal cord, and head. Types of tremors
are intention, postural, rest, and rubral (Alistair [16]). Cerebellar signs will be
evident with a significant involvement of the cerebellum. A pure cerebellar
syndrome is rare and other causes must be investigated. Tremors in cerebellar
involvement affect arms, legs, head, and trunk in descending order of frequency.
Face, tongue, and jaw were not affected in a study done by Alusi et al. [17].
2.5 Cerebrum
Symptoms involving the cerebral hemispheres correlate the site of lesion such
as the parietal, temporal, frontal, and occipital lobes. Symptoms are right- or
left-sided hemianaesthesia, hemiparesis, hemiplegia, or monoplegia and visual
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symptoms due to visual field defect. Aphasia or dysphasia and epilepsy are rare
symptoms noted in MS [13].
2.6 Symptoms of multiple sclerosis in chronic disease
Spasticity, cognitive dysfunction, fatigue, affective disorders, and sexual dys-
function are normally seen in chronic disease [13]. An in-depth history during the
first clinical assessment is a valuable asset to establishing the diagnosis.
3. Investigations in MS
3.1 Blood investigations
There are no blood investigations that are pathognomonic for the diagnosis of
multiple sclerosis. However, in order to rule out other neurological conditions that
canmimicMS, a completeworkout is necessary. Screening for connective tissuediseases
such as Systemic Lupus Erythematosus, antiphospholipid antibody, retroviral screen,
other autoimmune condition such as thyroid disease, infectious diseases, Lyme disease
and angiotensin converting enzyme are necessary [18].
3.2 Lumbar puncture
Lumbar puncture for CSF analysis is required as it can further assist in the
diagnosis as its presence reveals a risk of developing MS in patients with clinically
isolated syndrome [3, 5, 19]. In 2017, cerebrospinal fluid (CSF) is done to look for
oligoclonal band and immunoglobulin G (IgG), and a parallel serum sample need to
be taken as no OCB production is noted in the blood in multiple sclerosis.
Oligoclonal band and immunoglobulin G are indicative of intrathecal inflammation
which is B cell modulated from plasma cells seen in CNS inflammatory disease [20].
Distinctive CSF analysis will disclose slightly raised leucocyte count, B cells, or
plasma cells in cytological analysis and raised IgG synthesis [21]. Oligoclonal band
will be highly helpful in the event of other clinical features that are not diagnostic,
and furthermore it depicts dissemination in space. Lumbar puncture is
recommended in the following situations [5]:
• When clinical and MRI evidence is inadequate to make diagnosis of multiple
sclerosis, especially if treatment is considered
• When there are atypical features of clinically isolated syndrome and in
population where MS is less common such as children, older individuals, or
non-white populations
The Panel on Diagnosis of Multiple Sclerosis [5] cautions diagnosis of multiple
sclerosis early on in the disease and in children when OCB is negative in atypical
clinical, radiological, or OCB findings.
There are two methods of analysing the CSF for oligoclonal band agarose gel
electrophoresis/Coomasie Blue Staining and isoelectric focus/silver staining [22].
Oligoclonal bands are positive in up to 95% of patients with clinically definite
multiple sclerosis.
3.3 Evoked potentials
Evoked potentials are electrophysiological tests done to look for evidence of
silent lesions [23]. Abnormal or slowing of electrical conduction along the central
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nervous system pathway can be detected even when there are no obvious clinical
features seen. Visual evoked potentials are visual stimulation, which consists high
contrast black and white checkerboard where these squares, are changed places and
response to this reversal is recorded. Delayed waveform depicts an optic nerve
lesion. Brainstem evoked potentials are when auditory stimulations in the form of
clicks are given for a response obtained from the brainstem. It assesses lower
brainstem auditory pathway. The BAEP are abnormal when demyelination involves
brainstem. Somatosensory evoked potentials are obtained when stimulation from
the peripheral nerves in the upper limbs produces a response. An abnormal
response could translate to demyelination within the central fibres of dorsal
column-medial lemniscal pathways. Evoked potentials may not be useful with
advances in MRI techniques and oligoclonal band, and they have not been included
in McDonald criteria 2017.
3.4 Magnetic resonance imaging
Magnetic resonance imaging (MRI) is a neuroimaging of choice for diagnosis of
MS and plays a key role in research, surveillance, and treatment. Although the
McDonald criteria denote that two clinical attacks depicting dissemination in time
and space are sufficient to make a diagnosis, neurologists and neurologist with
interest in MS would require a baseline MRI to confirm diagnosis and for surveil-
lance. White matter lesions in the MRI are characteristic with typical juxtacortical,
cortical; periventricular, brainstem and spinal cord lesions are required. MRI
protocols used in MS are spin echo T2 weighted, fluid-attenuated inversion
recovery. The Consortium of MS Centres revised and updated guidelines for MRI
([24], ww.mscare.org/mri).
3.4.1 MRI protocols adapted from the Consortium of MS Centers
Baseline studies for patients with a clinically isolated syndrome (CIS) and/or
suspected MS:
• Brain MRI protocol with gadolinium at baseline and to establish dissemination
in time
• Spinal cord MRI if myelitis, insufficient features on brain MRI to support
diagnosis, or age > 40 years with nonspecific brain MRI findings
• A cervical cord MRI performed simultaneously with the brain MRI could
have prognostic value in the evaluation of CIS patients with or without myelitis
and would reduce the number of patients requiring a subsequent MRI
appointment
• Orbital MRI if severe optic neuritis with poor recovery
Timing of a follow-up brain MRI protocol for patients with a CIS and/or
suspected MS to look for evidence of dissemination in time (i.e. new T2 lesions or
gadolinium-enhancing lesions):
• 6–12 months for high-risk CIS (e.g. ≥ 2 ovoid lesions on first MRI)
• 12–24 months for low-risk CIS (i.e. normal brain MRI) and/or uncertain
clinical syndrome with suspicious brain MRI features (e.g. radiologic isolated
syndrome [RIS])
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Timing of brain MRI protocol for patients with an established diagnosis of MS:
• No recent prior imaging available (e.g. patient with established diagnosis
of MS and new to your clinical practice)
• Postpartum to establish a new baseline
• Prior to starting or switching disease-modifying therapy
• Approximately 6–12 months after switching disease-modifying therapy to
establish a new baseline on the new therapy
• Every 1–2 years while on disease-modifying therapy to assess for
subclinical disease activity (i.e. new T2 lesions or gadolinium-enhancing
lesions). Less frequent MRI scans required in clinically stable patients
after 2–3 years of stable treatment (gadolinium-based contrast optional)
• Unexpected clinical deterioration or reassessment of original diagnosis
(gadolinium-based contrast recommended)
• The use of gadolinium-based contrast agents is helpful but not essential
for detecting subclinical disease activity because new T2 MS lesions can be
identified on well-performed standardized MR imaging unless there is a
large T2 lesion burden, which may obscure new T2 lesion activity.
4. Diagnosis of MS with McDonald criteria
The International Panel on Diagnosis of Multiple Sclerosis consists of 30 mem-
bers of European, American, and Asian representatives who are experts in their
field, met in 2016 and 2017 to revise and formulate a new guideline based on
advances on MS. The criteria are to be used only in the setting of clinically isolated
syndrome to diagnose MS and progressive MS [5].
4.1 Optical coherence tomography
Optical coherence tomography (OCT) is a noninvasive cross-sectional imaging
in biological systems [26]. OCT assesses the peripapillary area of the retina. Retinal
nerve fibre layer and ganglion cell layer thickness loss affects visual function,
disability, and magnetic resonance imaging. OCT angiography is a new technique
under study in MS [27]. Retinal nerve fibre thinning is seen in multiple sclerosis,
and OCT is able to measure the loss. Fundoscopy is the clinical parallel of OCT.
5. Common differential diagnosis
Clinicians should bear in mind multiple sclerosis mimickers to ensure there is no
other possible explanation. Common differentials are connective tissue disease such
as systemic lupus erythematosus and antiphospholipid antibody syndrome.
Neuromyelitis optical spectrum disorder, which was previously known as Devic’s
disease, is an immune-mediated disorder that can be distinguished, from MS by
typical MRI lesions and/or anti-aquaporin 4 antibody. Other conditions are acute
disseminated meningoencephalitis, small vessel disease, and Susac’s syndrome.
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5.1 Neuromyelitis optica spectrum disorder
Neuromyelitis optica spectrum disorder is often considered as a differential of
MS. It was considered as a part and spectrum of Multiple sclerosis, till Aquaporin 4
antibody serum antibodies [28, 29] that target the water channel aquaporin 4 was
considered in the pathogenesis of NMOSD. It is essential to differentiate multiple
sclerosis and NMOSD as the treatment differs in both, and some treatment could be
harmful.
Diagnostic criteria for NMOSD[30].
Diagnostic criteria for NMOSD with AQP4-IgG
1. At least one core clinical characteristic
2. Positive test for AQP4-IgG using best available detection method (cell-based
assay strongly recommended)
3. Exclusion of alternative diagnoses
Diagnostic criteria for NMOSD without AQP4-IgG or unknown AQP4-IgG status:
1. At least two core clinical characteristic occurring as a result of one or more
clinical attacks and meeting all of the following requirement:
2. At least one core clinical characteristic must be optic neuritis, acute myelitis
with LETM, or area postrema syndrome
3.Dissemination in space (two or more core clinical characteristics)
4.Fulfilment of additional MRI requirements, as applicable
5. Negative test for AQP4-IgG using the best available detection method or
testing unavailable
6.Exclusion of alternative diagnoses
Core clinical characteristics:
1. Optic neuritis
2. Acute myelitis
3.Area postrema syndrome: episode of otherwise unexplained hiccups or nausea
and vomiting
4.Acute brainstem syndrome
5. Symptomatic narcolepsy or acute diencephalic clinical syndrome with
NMOSD-typical diencephalic MRI lesions
Symptomatic cerebral syndrome with NMOSD-typical brain lesions
Additional MRI requirements for NMOSD without AQP4-IgG or unknown
AQP4-IgG status:
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• Acute optic neuritis
• Requires brain MRI showing
• Normal findings or only nonspecific white matter lesions, OR
• Optic nerve MRI with T2-hyperintense lesion, or T1-weighted
gadolinium-enhancing lesion extending over 1/2 optic nerve length or
involving optic chiasm
• Acute myelitis: requires associated intramedullary MRI lesion extending over
three or more contiguous segments (LETM) OR three or more contiguous
segments of focal spinal cord atrophy in patients with history compatible with
acute myelitis
• Area postrema syndrome: requires associated dorsal medulla/area postrema
lesions
• Acute brainstem syndrome: requires associated periependymal brainstem
lesions.
5.2 MOG antibody disease
Seronegative NMOSD patients have been associated with MOG antibody
disease, which is a myelin oligodendrocyte glycoprotein and which is found only
in the central nervous system. Myelin oligodendrocyte glycoprotein is a small
part of myelin [31]. MOG can be found in extracellular surface of myelin
sheaths and oligodendrocytes. MOG antibodies were seen in several
demyelinating diseases of the central nervous system disorders [32, 33].
MOG antibody disease tends to favour women, which is one third of
patients (Figure 1).
B-cell activation is the strongest element seen in central nervous system of
multiple sclerosis patients. Central nervous system-directed antibodies are pro-
duced in the periphery in neuromyelitis optica and myelin oligodendrocyte glyco-
protein antibody disease. MRZ reaction is antibodies against measles, rubella, and
varicella zoster (Tables 1–3).
5.3 Acute disseminated encephalomyelitis
Acute disseminated encephalomyelitis (ADEM) is a central nervous system-
demyelinating disease predominantly involving children and young adults. It has
been noted in adults and elderly; it follows vaccination and postinfectious state. It is
commonly monophasic and rarely multiphasic in nature, and it can involve the
brain, spinal cord, and optic nerves as in multiple sclerosis. Fever, malaise, myal-
gias, headache, nausea, and vomiting can precede neurological symptoms of
ADEM, which can begin 4–21 days after the antecedent event. Clinical features of
ADEM are the development of a focal or multifocal neurological disorder which
could be encephalopathy, coma, and focal and multifocal neurological signs like
hemiparesis, cranial nerve palsies, paraparesis, meningismus, ataxia, movement
disorders, and seizure [36]. The International Paediatric Multiple Sclerosis Study
Group (IPMSSG) [37] proposed consensus definitions for paediatric-acquired
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demyelinating disorders of the CNS to clarify the terminology for demyelination
disease, and this was further updated in 2013 [38]. ADEM criteria require the
following:
Monophasic ADEM:
i. A first polyfocal clinical neurological event with presumed inflammatory cause
ii. Encephalopathy that cannot be explained by fever is present
iii. No new clinical or radiological evidence of a new event suggestive of ADEM
after 3 months
Multiphasic ADEM
i. A new onset of ADEM in 3 or more months after the primary event
ii. A new onset or reappearance of ADEM linked to previous clinical or
radiological event involving the central nervous system
iii. Time of symptom onset in relation to steroids has no relevance
ADEM should be a diagnosis of exclusion and should be differentiated from
multiple sclerosis from its clinical and radiological profile.
Figure 1.
Biomarkers in Multiple sclerosis, Neuromyelitis Optica Spectrum Disorder and MOG antibody disease. MRZ
reaction are antibodies against measles, rubella and varicella zoster. (Adapted from [34]).
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Protocol 1: Standardised brain MRI protocol (diagnosis and routine follow-up of MS)
Field strength Scans should be of good quality, with adequate signal-noise ratio (SNR) and
spatial resolution (in-slice pixel resolution of ≤1  1 mm)
Scan prescription Use the subcallosal plane to prescribe or reformat axial oblique slices
Coverage Whole brain coverage
Slice thickness and
gap
≤ 3 mm, no gap (for 2D acquisition Or 3D1 reconstruction)
Core sequences 2D/3D sagittal and Axial FLAIR1,2. 2D/3D axial T21
Axial 2D DWI3
3D IR-Prep GE4 T1
Gadolinium5 (as
required)
Post-gad 2D/3D axial T1
Additional sequences Susceptibility-weighted imaging (SWI). Pre-gad 2D/3D axial T1
Axial proton density
1. 3D acquisition should be isotropic ≤1  1  1 mm
2. Fluid attenuated inversion recovery (FLAIR)
3. Diffusion-weighted imaging (DWI)
4. Inversion recovery-prepared gradient echo (IR-Prep GE); magnetization-prepared rapid
acquisition gradient echo or MP-RAGE; turbo field echo Or TFE
5. Single dose of gadolinium-based contrast agent as required (note that the FLAIR Or T2 may be
performed during the 5-minute minimum delay after gadolinium injection before acquiring the
post-gadolinium T1)
Protocol 2: PML surveillance brain MRI protocol
Field strength Scans should be of good quality, with adequate signal-noise ratio (SNR) and
resolution (in-slice pixel resolution of ≤1  1 mm)
Scan prescription Use the subcallosal plane to prescribe or reformat axial oblique slices
Coverage Whole brain coverage
Core sequences1 2D/3D sagittal and axial FLAIR2 axial 2D DWI3
Gadolinium (can be
helpful) 4
Post-gad 2D/3D axial T1
Additional sequences DWI
2D/3D axial T2
3D IR-Prep GE5 T1
Pre-gad 2D/3D axial T1. Axial proton density
Slice thickness and
gap
< 3 mm, no gap (for 2D acquisition or 3D reconstruction)
1. Typical PML lesions may appear hyperintense on FLAIR, hypointense on T1, and high signal
intensity on DWI
2. Fluid attenuated inversion recovery (FLAIR)
3. Diffusion-weighted imaging (DWI)
4. Less than 50% of PML lesions will show contrast enhancement
5. Inversion recovery-prepared gradient echo (IR-Prep GE); magnetization-prepared rapid
acquisition gradient echo or MP-RAGE; turbo field echo or TFE
Protocol 3: Spinal cord MRI protocol
Field strength Scans should be of good quality, with adequate signal-noise ratio (SNR) and
resolution (in-slice pixel resolution of ≤1  1 mm)
Coverage Cervical cord coverage1
Core sequences Two of the following: sagittal T2
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Proton density STIR2
T1-PSIR3
Axial T2/T2* through lesions
Slice thickness and
gap
Sagittal: <3 mm, no gap. Axial: <5 Mm, no gap
Additional sequences Sagittal T1
Post-gad T14 (sag, axial)
Axial T2/T2* entire cervical cord 3D IR-Prep GE5 T1
1. Thoracic and conus coverage recommended if symptoms localize to this region to rule out an
alternate diagnosis
2. Short tau inversion recovery (STIR)
3. Phase-sensitive T1 inversion recovery (PSIR)
4. No additional gadolinium necessary if cord examination immediately follows gadolinium-
enhanced brain MRI
5. IR-Prep GE (inversion recovery-prepared gradient echo); magnetization-prepared rapid
acquisition gradient echo or MP-RAGE; turbo field echo or TFE
Protocol 4: Orbit MRI protocol
• May be clinically indicated to confirm optic neuritis and rule out compressive lesions
• Recommended sequences include coronal STIR or fat-suppressed T2 and a post-gadolinium fat-
suppressed T1 with a section thickness of ≤2 Mm, with coverage to include the optic chiasm
• Optional sequences may include axial/coronal pre-gadolinium fat-sat T1, axial fat-sat T2 or STIR,
and axial post-gad fat-sat T1
Recommendations for communication
MRI requisition:
The clinician should provide on the request for the standardized MRI brain and/or spinal cord protocol:
• Clinical questions to be addressed *diagnosis
*Monitoring for management decision
• Relevant clinical history and physical examination findings
• Current MS disease-modifying treatment and JC virus status if on natalizumab
• If known, date and place of previous examinations
MRI report:
Standardised nomenclature/terminology should be used and include:
1. Description of findings
• *Lesion type, location, size, shape, character, number for diagnostic
Scan
• *CIS diagnostic scan: whether meets current MRI dissemination in
space or dissemination in time criteria
• *Qualitative assessment of T2 and brain volume/atrophy
2. MS monitoring or CIS follow-up: comparison with previous studies (new lesions, atrophy)
3. Interpretation (typical for MS, atypical for MS, not MS) and differential diagnosis, if appropriate
Note: structured reports can be helpful (Alessandrino et al., Ajr, 2018; Dickerson et al., J Am Coll
Radiol 2017).
Recommendations:
*Studies should be stored in a DICOM format.
*Copies of MRI studies should be retained permanently and be available.
*It is strongly recommended for patients to keep their own studies on
Portable digital media
Table 1.
MRI protocols (Adapted from [25]).
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5.4 Antiphospholipid antibody syndrome
The antiphospholipid syndrome (APS) is a systemic autoimmune disorder with
arterial and venous thromboses; recurrent foetal loss, often accompanied by
thrombocytopenia; raised antiphospholipid antibodies, namely, lupus
anticoagulant; and anticardiolipin antibodies [39]. Common presentations
that can mimic MS are stroke-like presentations such as transient ischemic attack,
ischemic stroke, venous thrombosis, epilepsy, headache, movement disorder,
transverse myelitis, cognitive impairment, and other neuropsychiatric
manifestations.
5.5 Systemic lupus erythematous
Systemic lupus erythematous is an autoimmune condition that is frequency
associated with neuropsychiatric manifestations and neurological deficit [13].
Table 2.
McDonald criteria 2017.
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6. Conclusion
Multiple sclerosis can be challenging to make a diagnosis unless a clinician is
familiar with the disease. No better explanation for the condition is essential to
come to a conclusion regarding the diagnosis. A good history, elaborate and exten-
sive clinical examination, lumbar puncture, magnetic resonance examination, and
blood investigations are required. The McDonald criteria have facilitated the
diagnosis of multiple sclerosis for precision and allowing earlier diagnosis.
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